Johnson & Johnson has three buyers in its latest consumer health product divestment. Rights to its 1% ketoconazole anti-dandruff shampoo, branded Nizatrol A-D in the US, are going to a separate firm for each of the US-Latin America, Asia-Pacific and Europe-Middle East-Africa regions.
J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.